Neurology Devices Market Size & Share 2025 - 2034

Neurology Devices Market Size

The global neurology devices market size was valued at USD 14.3 billion in 2024. The market is expected to reach from USD 15.1 billion in 2025 to USD 28.3 billion in 2034, growing at a CAGR of 7.2% during the forecast period. The high market growth can be attributed to technological advancements, the rising prevalence of neurological disorders, improved access to healthcare facilities and increased healthcare expenditure, among other contributing factors.

The growing global burden of these conditions is underscoring the necessity for more effective diagnostic tools and treatment methods. For example, an article published by The Lancet Neurology, reported that in 2021, over 3 billion people were estimated to be suffering from neurological disorders, and more than one third of the global population suffers from Alzheimer’s, Parkinson’s disease, epilepsy, and strokes. As a result, these disorders constitute one of the leading causes of illness and disability globally.
 

Moreover, the new technologies such as brain-computer interfaces and AI based remote monitoring systems have greatly enhanced the effectiveness of treatment provided to the patients. The introduction of some new minimally invasive neurotechnology such as deep brain stimulators (DBS) and portable EEG monitors has greatly advanced these technologies in the field of neurological care.
 

A neurology device is considered to be a surgical tool, implantable device or diagnostic equipment that deals with a surgical condition relating to the nervous system, which includes the brain, the spinal cord and the peripheral nerves. Such devices can be categorized into diagnostic devices, surgical instruments and implant systems.
 

Neurology Devices Market Trends

The market is witnessing significant growth driven by advancements in neurotechnology, surge in neurostimulation and neuromodulation devices, increasing prevalence of neurological disorders, and growing demand for integrated artificial intelligence (AI) in healthcare and robotics, among other factors are boosting the industry growth.
 

• The increasing adoption of subtle interventional techniques by patients and healthcare practitioners is fostering greater demand for neurological devices. For instance, the American Association of Neurological Surgeons (AANS) reported that in 2023, nearly 75% of brain operations were performed using minimally invasive methods compared to 60% in 2021.
   

The Centers for Medicare and Medicaid Services reported a 35% increase in reimbursements for minimally invasive neurological procedures between 2021 and 2023. These devices reduce complications associated with traditional surgical methods and decrease patient recovery time by up to 40%, as per the National Institute of Neurological Disorders and Stroke (NINDS) 2024 report.
 

• In addition, availability of neurology care is getting better, especially in underserved areas due to the expansion of tele-neurology services along with cloud-based platforms for patient monitoring. This is further driving demand for neurology devices.
   
• Further, AI-powered neurology devices are revolutionizing diagnostics and treatment due to their ability of real time analysis of brain activity and improving accuracy of identifying neurological conditions. These technologies have significantly improved early diagnosis and patient care, thereby the above factors are contributing to the growing market demand.
   

Trump Administration Tariffs

• The Trump administration's policies on trade tariffs may create significant impact to the U.S. neurology devices market in terms of expenditures, innovation, and even the medical supply chains of the country. Since 69% of the marketed medical devices are manufactured outside the country, the Trump tariffs may create a colossal problem for the industry.
   
• Foreign manufacturing dependence has compounded the challenges already facing the production of medical devices. Companies such as L&K Biomed that fully outsource production will be heavily impacted. Furthermore, the supply-in-demand balance seems to contradict itself due to the pandemic which increases the prices of medical devices overall.
   
• It is imperative for companies to rethink their manufacturing policies in light of the new tariffs, which is in fact encouraging some near-shoring strategies like moving manufacturing bases to Mexico, one of the fastest growing countries in medical device manufacturing. However, tariffs on imports from Mexico may disrupt these plans too, causing more inefficiencies within the supply chains.
   
• In addition, the most recent increase in costs and supply chain factors bring uncertainties which may inhibit innovation in the field of neurology devices. Rehabilitation companies will have less capital to invest in research and development that is necessary to provide products that enhance the patients’ quality of life. More specifically, startups and smaller companies may find it difficult to absorb the compounded costs or supply chain changes, stunting their growth or driving them out of the market altogether.
   
• Overall, the Trump administration's tariffs will create some of the most serious challenges for the U.S. market pertaining to costs, supply chains, and innovation. Companies are dealing with these issues by changing their manufacturing approaches and looking for ways to innovate to counter the negative impacts of these policies.
   

Neurology Devices Market Analysis

Based on device, the market is classified into neurostimulation devices, neurosurgical devices, interventional neurology devices, brain-computer interface devices, and other devices. The neurostimulation devices segment generated the highest revenue of USD 7 billion in 2024.
 

• Neurostimulation devices include spinal cord stimulators, deep brain stimulators (DBS), vagus nerve, and sacral nerve stimulators. These devices assist in the management of epilepsy, movement disorders, chronic pain, and psychiatric conditions. The World Health Organization (WHO) reported in 2023 that roughly 50 million people globally have epilepsy, and close to 10 million are diagnosed with Parkinson's disease.
   
• In addition, the Centers for Disease Control and Prevention (CDC) report published in 2022 stated that migraine affects approximately 37 million people in the U.S. The same report, as well as the 2021 National Institute of Mental Health data, indicates that 21% of U.S. adults live with some form of mental illness. The rise in the prevalence of such neurological diseases increases the need for these therapeutic solutions.
   
• Moreover, new and more precise neurostimulation devices such as closed loop systems, MRI compatible implants, and miniaturized devices are continuously improving precision and safety. These advancements increase the effectiveness of patients and widen the therapeutic uses of neurostimulation devices, thereby accelerating growth in the market.
   
• Further, the use of these devices has expanded to treat resistant depression, migraine, and chronic back pain. This movement disorder therapeutic scope is appealing to investment and is broadening the potential market for neurostimulation devices.
   

Based on application, the neurology devices market is classified into chronic pain management, Parkinson’s disease, epilepsy, stroke management and recovery, Alzheimer, and other applications. The chronic pain management segment accounted for USD 4.6 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 7.6% between the 2025 to 2034 period.
 

• Chronic disorders such as neuropathic pain, back pain, and fibromyalgia are prevalent in the global population and have been achingly common in older citizens for years. As of 2022, the CDC noted that about 20.4% of adults surveyed across the U.S. reported having chronic pain, with those aged 65 and older having an even higher percentage. As of 2023, The WHO reported that approximately 30% of the adult population globally suffers from chronic pain.
   
• There is an increasing need for neurological devices with spinal cord stimulators and peripheral nerve stimulators owing to these agonizing ailments, as they are not effectively treated with pharmaceuticals. Between 2021 and 2023, Medicare data noted a 12% rise in spinal cord stimulator implantation, illustrating a wider acceptance and use of these devices among patients suffering with chronic pain.
   
• Moreover, expansion of devices used to manage chronic pain is possible due to high patient compliance stemming from the addition of features like high-frequency stimulation, closed-loop feedback systems, and wireless controls that offer ease and effectiveness. These features provide better adherence from patients and broaden the range of debilitating chronic pain conditions requiring devices.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the neurology devices market is classified into hospitals, ambulatory surgical centres and other end users. The hospital segment dominated the market in 2024 with a market share of 56.1%.
 

• Hospitals handle a large share of diagnostic and therapeutic procedures for neurological disorders, including strokes, epilepsy, brain tumors, and neurodegenerative diseases. Their comprehensive infrastructure enables them to use a wide range of neurology devices, from neuroimaging systems to neurostimulation tools, driving demand in this setting.
   
• Further, these centers also perform the most critical parts of emergency neurology procedures which include stroke thrombosis, trauma care, and seizure management. Due to this core role and the necessity for continual refinement and repetitive function, there is an endless need for advanced neurological devices that reinforces consistent demand in these settings.

U.S. neurology devices market accounted for USD 5.2 billion market revenue in 2024. The U.S. dominated the global market in 2023 with USD 4.9 billion growing from USD 4.7 billion in 2022 and is anticipated to grow at a CAGR of 6.8% between 2025 to 2034 period.
 

• The increasing adoption of neurology devices is being triggered by the growing prevalence of neurological disorders in the U.S. The Centers for Disease Control and Prevention (CDC) reported that stroke was the fifth most common cause of mortality in the country in 2021. This statistic alone underscores the critical requirement for appropriate stroke treatment, thus driving demand for neurological devices.
   
• The U.S. continues to be the largest source of funding for neurological research, receiving the highest amount of grants and approvals as well as conducting most clinical trials, which streamlines the use of new and sophisticated neurology devices. Funding agencies such as the National Institutes of Health (NIH) and the BRAIN Initiative spend billions on research pertaining to neural stimulation, brain-computer interfacing, and neuroprosthetics.
   
• Furthermore, there is a widening gap in the prevalence of age-related neurological disorders and the availability of adequately trained professionals, which is being fueled by the growing elderly demographic. The U.S. Census Bureau has estimated that by 2030, roughly 20% of the American populace will be aged 65 or older. This drives continued demand for stroke rehabilitation and cognitive therapy programs, as well as neurostimulation implants.
   

North America dominates the global neurology devices market in 2023 with USD 5.2 billion growing at CAGR of 6.9%.
 

• Continuous investments in healthcare and medical device infrastructure across U.S. and Canada has kept the North America, a top performing region across the globe.
   
• Hospitals in North America usually have advanced neurology devices such as MRI, CT, EEG, and deep brain stimulation systems. These also contain neurospecialists and trained personnel which are crucial for the correct functioning and analysis as well as the smooth workflow for these devices and so improves the usage rate of these devices.
   

Germany neurology devices industry in the Europe is projected to grow remarkably in the coming years.
 

• Germany is fostering the digital innovation of healthcare systems, especially within the neurology discipline. For instance, the government’s Hospital Future Act of 2020 supports the implementation of tele-neurology, AI neuroimaging, and robotic neurosurgery. These developments have advanced the efficiency of treatment provided and permitted earlier diagnoses of neurological disorders.
   
• Germany is also rapidly becoming innovative in device with other key players in the field, like B. Braun and Brainlab and renowned research institutions. Their constant investment in sophisticated neurological technology accelerates the growth and widespread use of new neurological devices.
   
• Further, the relatively simple and fast regulatory approval processes in Germany enable new devices to be introduced to the market quicker compared to other countries, creating a lower entry barrier. This facilitates the widespread availability of innovative treatments and increase the growing market needs for neurology devices.
   

Japan holds a dominant position in the Asia Pacific neurology devices market.
 

• Japan's aging population 29.1% of individuals were over 65 years old in 2023, according to the Ministry of Internal Affairs and Communications is experiencing rising rates of neurological conditions such as Alzheimer's disease, stroke-related disorders, and Parkinson's disease. This demographic trend is driving increased demand for neurology devices, including deep brain stimulators, brain-computer interfaces, and neurorehabilitation systems.
   
• Japan is one of the global leaders in robotics, as such it swiftly integrates AI and robotics which greatly enhances the precision of treatment, patient mobility, and cuts down the time it takes for patients to fully recover. As a result, neurology devices are becoming more efficient and their use is being fast-tracked.
   
• In addition, the country’s telemedicine systems provide advanced remote diagnostics and treatment of neurological disorders. Increasing partnerships between hospitals and other research institutions with device manufacturing companies are boosting the adoption of smart neurology devices within the country.
   

The Brazil neurology devices market is experiencing robust growth in Latin America market.
 

• Brazil's public and private healthcare sectors have been scaling up investments in and gaining access to neurological services and devices throughout the country. In 2023, healthcare spending in Brazil reached 9.7% of its GDP, up from 9.2% in 2021.
   
• The Ministry of Health set aside USD 33.2 billion for healthcare initiatives in 2024, marking a 12% increase from 2022. Within this budget, USD 2.7 billion was set aside specifically for medical equipment and infrastructure development. This increased spending seems to be accelerating the adoption of neurological devices across the country.
   
• In addition, the general Brazilian population along with health professionals have started to recognize neurological disorders alongside the importance of diagnosis at early stages. This increases the readiness and usage of devices to manage and detect neurological disorders and diseases.
   

Neurology Devices Market Share

The market is characterized by the presence of several key players, including Medtronic, Abbott Laboratories, Boston Scientific, and Stryker, which together hold approximately 34% of the market share. These companies compete by offering innovative, FDA-approved devices specifically designed for neurological disease management, aiming to optimize clinical outcomes and enhance patient safety.
 

Additionally, they invest heavily in research and development to develop robotic-assisted neurosurgery solutions, integrate telehealth capabilities, and enable real-time patient monitoring—efforts that help expand their market share and improve patient care. Technological advancements in neuromodulation and neurovascular interventions, along with strategic pricing, regulatory approvals, and global market expansion, are other key competitive factors. These institutions continue to strengthen their market positioning in an increasingly dynamic and rapidly evolving landscape.
 

Neurology Devices Market Companies

Prominent players operating in the neurology devices industry include:

• Abbott Laboratories
• B BRAUN
• Bioness
• Boston Scietific
• enterra medical
• KARL STROZ
• LivaNova
• Medtronic
• MicroTransponder
• NeuroPace
• nevro
• Paradromics
• stryker
• synchron
• ZYLOX TONBRIDGE
   
• Medtronic offers a comprehensive portfolio in the neurology division with its neurovascular, neurosurgical and neurostimulation devices that offers efficient treatment for stroke management, movement disorders and chronic pain.
   
• Abbott Laboratories offers a remote neuromodulation programming platform, NeuroSphre Virtual Clinic, that allows physicians to adjust brain and spinal stimulation therapies through tele-medicine.
• Companies invest heavily in research and development, focusing on developing minimally invasive neurology devices for stroke and other neurological conditions.
   

Neurology Devices Industry News

• In February 2025, Medtronic has received FDA approval for its of BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) to treat people with Parkinson’s disease. This approval strengthens the company’s position in the market by offering personalized, real-time therapy, giving the company a competitive edge and expanding its market share in advanced DBS solutions.
   
• In September 2024, Stryker acquired NICO Corporation to provide a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition further strengthens Stryker's commitment to neurotechnology through tumour and stroke care.
   
• In August 2021, MicroTronsponder received FDA approval for its Vivistim Paired VNS System, a drug free rehabilitation technology that helps in treating moderate or severe upper extremity motor deficit in stroke patients. The Vivistim works by stimulating vagus nerve and help in improving patients ability to move arms and hands. This approval helped the company in strengthening its position in market.
   

The neurology devices market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Device

• Neurostimulation devices                      
  • Spinal cord stimulators
  • Deep brain stimulators
  • Vagus nerve stimulators
  • Sacral nerve stimulators
  • Gastric electrical stimulators

• Neurosurgical devices
  • Stereotactic systems
  • Neuroendoscopes
  • Ultrasonic aspirators
  • Aneurysm clips
• Interventional neurology devices
  • Aneurysm coiling and embolisation                   
    • Embolic coils 
    • Flow diversion devices       
    • Liquid embolic reagents
  • Neurothromobectomy
    • Clot retrievers
    • Suction aspiration devices
    • Snare devices
  • Neurovascular catheters    
    • Micro catheters
    • Micro guidewires
  • Cerebral balloon angioplasty and stents
    • Carotid artery stents
    • Filter devices
    • Balloon occlusion devices
  • CSF management devices
    • Cerebral shunts
    • Cerebral external drainage

• Brain-computer interface devices

• Non-invasive BCI
• Partially invasive BCI
• Fully invasive BCI

• Other devices

Market, By Application

• Chronic pain management
• Parkinson’s disease
• Epilepsy
• Stroke management and recovery
• Alzheimer
• Other applications

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE